Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.
| Condition | Intervention | Phase |
|---|---|---|
|
Triple Negative Breast Cancer |
Drug: Paclitaxel plus carboplatin Drug: Paclitaxel and epirubicin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Treatment in Locally Advanced Triple-negative Breast Cancer |
- Pathology of specimens derived from the breast modified radical mastectomy/Breast-conserving surgery [ Time Frame: One week after the surgery ] [ Designated as safety issue: Yes ]After patients complete the neoadjuvant chemothreapy and receive the surguries,we can get their pathology ，and compare the pCR（pathological complete remission）rates of two amrs
- follow-up the patient every 3-6 months to obtain the 3 year-DFS(disease free survival ) and OS(overall survival ) [ Time Frame: we follow up the patients every 6 month ,up to 3 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 80 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | July 2012 |
| Estimated Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: ET
The control arm receive the paclitaxel plus epirubicin
|
Drug: Paclitaxel and epirubicin
Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v. 1 cycle = 21days 2-6cycles |
|
Experimental: PC
the experimental arm which receive the paclitaxel combined with carboplatin
|
Drug: Paclitaxel plus carboplatin
Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v. 1 cycle = 21days 2-6cycles |
Detailed Description:
It is know that triple-negative breast cancer(TNBC) is more aggressive than non-triple negative breast cancer in both pathological features and clinical prognosis,and there is no standard chemotherapy regimens especially for TNBC. NCCN guidelines recommends Paclitaxel or Epirubicin based regimens as the preferred regimens both for the adjuvant chemotherapy and the treatment of Recurrence and Metastatic breast cancer.The combination of these two drugs is considered as a strong arrangement and therefore,is common used in Triple negative breast cancer patients because of its poor prognosis.
According to the results of some retrospective studies, platinum-based chemotherapy regimens showed a promising sensitive to Triple negative breast cancer patients compared with regimens without platinum.
This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women aged from 18 to 70 years;
- WHO Performance status (ECOG) of 0 or 1
- Core biopsy histologically proven Ⅱa-Ⅲc phase breast cancer (regardless of the type);
- Immunohistochemisty（IHC）：ER-，PR-，CerB2-；Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER<10%, PR<10% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH negative]；
- Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin > 9 g/dl);
- Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN,total bilirubin £ 1,5 ULN;
- Adequate renal function: serum creatinine £ 1.5 ULN;
- Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography，and electrocardiogram doe not show specific abnormality；
- Patients accepting contraception intake during the overall length of treatment if of childbearing potential;
- Signed written informed consent.
Exclusion Criteria:
- Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);
- ER+ or PR+ or Her-2 overexpression
- Any chemotherapy, hormonal therapy or radiotherapy before
- Previous cancer in the preceding 10 years;
- Patients already included in another therapeutic trial involving an experimental drug;
- Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study;
- LEVF < 50% (MUGA scan or echocardiography);
- Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to chemotherapy;
- Known prior severe hypersensitivity reactions to agents that will be received;
- Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase;
- Women with a positive pregnancy test en enrollment or prior to study drug administration;
- Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
- Individual deprived of liberty or placed under the authority of a tutor.
Contacts and Locations| Contact: ZHANG Pin, BD | +861087788120 | zhang_pin@sina.com |
| Contact: YIN Yi, BD | elovf1@163.com |
| China, Beijing | |
| Cancer institute &Hospital，Chinese Academy of Medical Sciences | Recruiting |
| Beijing, Beijing, China, 100021 | |
| Contact: ZHANG Pin, BD +861087788120 zhang_pin@163.com | |
| Contact: YIN Yi, BD elovf1@163.com | |
| Principal Investigator: ZHANG Pin, BD | |
| Principal Investigator: | ZHANG Pin, BD | Cancer Institute Hospital, Chinese Academy of Medical Sciences |
More Information
Additional Information:
No publications provided
| Responsible Party: | ZHANG Pin, Medicine Oncology Department, Chinese Academy of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01276769 History of Changes |
| Other Study ID Numbers: | LC2010A03 |
| Study First Received: | December 10, 2010 |
| Last Updated: | November 15, 2011 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Chinese Academy of Medical Sciences:
|
Triple Negative Breast Cancer Neoadjuvant chemotherapy Platinum |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Epirubicin Carboplatin Paclitaxel Antibiotics, Antineoplastic |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Phytogenic |
ClinicalTrials.gov processed this record on May 19, 2013